We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bayer AG | TG:BAYN | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.13 | -0.46% | 28.15 | 28.08 | 28.22 | 28.49 | 27.81 | 28.345 | 232,091 | 22:50:04 |
From May 2019 to May 2024
By Kim Richters
Bayer AG over the weekend presented two new studies and results for its blood thinner Xarelto.
The German pharmaceutical and chemical company said the drug plus aspirin reduces the combined risk of limb ischemia and major cardiovascular events for patients who have a symptomatic peripheral artery disease after revascularization.
The results are from the Phase 3 VOYAGER PAD study, the company said.
Another study showed that Xarelto lowers the risk of major venous thromboembolism after minor orthopaedic surgery, Bayer said.
This data is from the from the clinical Phase 3 trial PRONOMOS, it said.
Write to Kim Richters at kim.richters@wsj.com
(END) Dow Jones Newswires
March 30, 2020 02:39 ET (06:39 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Bayer Chart |
1 Month Bayer Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
